This is a study by the Apollo group Chennai, India. 22 patients with oral cavity and oropharyngeal cancers treated with IMPT were reviewed. The average mean dose received by the oral mucosa (OM) was significantly less in IMPT plans compared to the IMRT plans generated by Tomotherapy (HT). There was a 7% absolute and 16.5% relative reduction in NTCP for grade 3 mucositis for OM, however, the study reported acute grade III dermatitis, mucositis and dysphagia in 50%, 45.5% and 22.7% patients. The authors attributed the discordance between NTCP and actual high incidence of mucositis to the use of concurrent systemic therapy and associated comorbidities. Five patients required hospital admission during treatment, with an average hospital stay of 3 days. At a median follow-up of 15 months, 16 (72.7%) were alive without disease, and 2 (9%) were alive with disease.